Page last updated: 2024-10-28
hydroxyurea and Thoracic Diseases
hydroxyurea has been researched along with Thoracic Diseases in 1 studies
Thoracic Diseases: Disorders affecting the organs of the thorax.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Clinical complications of sickle cell anemia begin in infancy." | 2.77 | Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. ( Brown, RC; Casella, JF; Howard, TH; Iyer, RV; Lebensburger, JD; Lu, M; Miller, ST; Rogers, ZR; Sarnaik, S; Wang, WC, 2012) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Lebensburger, JD | 1 |
| Miller, ST | 1 |
| Howard, TH | 1 |
| Casella, JF | 1 |
| Brown, RC | 1 |
| Lu, M | 1 |
| Iyer, RV | 1 |
| Sarnaik, S | 1 |
| Rogers, ZR | 1 |
| Wang, WC | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG)[NCT00006400] | Phase 3 | 193 participants (Actual) | Interventional | 2000-08-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Change From Baseline in the Renal Function That Was Measured by Diethylenetriaminepentaacetic Acid (DTPA) Glomerular Filtration Rate (GFR)
DTPA GFR was originally a co-primary efficacy outcome for the study. Later in May 29, 2009, this measurement was discontinued because of statistical futility (an extremely small chance that the difference between treatment groups would be statistically significant for this outcome) and the small risk posed by the radiation exposure involved with performing the DTPA GFR test. Subjects who had missing data at baseline or 2 years measurement were excluded from the analysis (29 subjects from the hydroxurea, and 31 subjects from the placebo group excluded). (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years
| Intervention | mL/min/1.73m^2 (Mean) |
|---|
| Hydroxyurea | 22.56 |
| Placebo | 20.74 |
Change From Baseline in the Renal Function That Was Measured by GFR (Calculated Using New Schwartz Formula)
GFR was calculated using new Schwartz formula: 39.1× [height (cm)/serum creatinine (mg/dL)]0.516 × [1.8/cystatin C]0.294 × [30/blood urea nitrogen]0.169 × [1.099]if male × [height(m)/1.4]0.188. Children with missing baseline or 2 years GFR were excluded from the analysis. (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years
| Intervention | mL/min/1.73m^2 (Mean) |
|---|
| Hydroxyurea | 10.57 |
| Placebo | 14.33 |
Change From Baseline in the Renal Function That Was Measured by Glomerular Filtration Rate (GFR) (Calculated Using Schwartz Formula)
Schwartz formula used to calculate GFR is: 0.55× height (cm)/serum creatinine (mg/dL). Where height is in cm and serum creatinine is in mg/dL. Children with missing baseline or 2 years GFR were excluded from the analysis. (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years
| Intervention | mL/min/1.73m^2 (Mean) |
|---|
| Hydroxyurea | 28.65 |
| Placebo | 33.36 |
Trials
1 trial available for hydroxyurea and Thoracic Diseases